



FORWARD-LOOKING STATEMENTS

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances.

Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Senfina may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

- EXECUTIVE & MANAGEMENT TEAM
- COMPANY OVERVIEW
- MARKET OVERVIEW AND UNMET NEEDS
- SENFINA OVERALL SERVICES
- SENFINA PRODUCTION
- PRODUCTS
- SENFINA PROJECTS
- TRADING & DISTRIBUTION CHANNELS
- FINANCIALS & INVESTMENTS
- ALTERNATIVE MARKET WITH VETERINARY PRODUCTS
- PROPOSAL





EXECUTIVE & MANAGEMENT TEAM



INTRODUCTION



Ray Patel
Chairman



Shakir Mughal
CEO

Senfina stands as a unique Contract Manufacturing and Development Organization (CMDO) that has been meticulously designed from inception to adhere to a comprehensive 360-degree Good Manufacturing Practice (GMP) framework. Our company possesses not only the necessary factory capacity but also the skilled personnel and industry expertise to efficiently execute operations within required timelines, effectively meeting the demands of the market.

Unlike traditional CMDOs, Senfina is not confined to a single product, which enables us to seize diverse opportunities in producing other vital and highly sought-after medicines. The significance of the CMDO model has become evident due to the future market demand.

As an active participant in the market, our company introduces progressive approaches and extends support to small-scale drug developers in scaling up their production capabilities, thus enhancing the accessibility of important treatments.

Already at present, Senfina has secured several customers with an anticipated demand of 1.7 billion doses of medical liquids starting from 2023. A portion of this demand is being fulfilled by the operational trading wing of Senfina, which originated from its predecessors, Synergy Forte and Interport.

We pride ourselves on being a flexible company equipped with modern manufacturing capabilities and scientific potential, enabling us to stay abreast of current trends and provide solutions to the most complex challenges.



BOARD OF DIRECTORS



Ray Patel
Chairman



Shakir Mughal
CEO



Jean Luc Eich
Managing Director



Dr. Carin Heringa
Board Member



Dr. Tom Pulles
Head Medical



Jayaram Sathyanarayana
Board Member

MANAGEMENT TEAM



Jean Luc Eich
Managing Director



Susanne Arndgen
Head of Engineering



Attila Santa
Head Business Unit



Sven Floer
CFO



Dr.Nandor Santa
Head Development



Yuliya Chepurna
Interface Manager&HR




Edit Santa
Head Accounting



Stefanie Erol
Head HSE



Sofia Pugna
Head of QA



Roxana Begu
Head of Production

WE ARE SENFINA



Attila Santa

Edit Santa

Shakir Mughal

Dr. Nandor Santa

Yuliya Chepurna

Jean Luc Eich


Alexandra Epure

WE ARE SENFINA

MANAGEMENT TEAM IN BRASOV



SENFINA NUMBERS



4

Locations:
Switzerland
United Kingdom (UK),
United Arab Emirates (UAE)
Romania

250

Employees spread in
over 4 countries

> 20 products

Products are
currently produced

> 40 products

Currently 15 Products for OSD are
under registration, 9 products in different
strength for OSD and 17 liquid products
(vaccines) are planned for future production

100 %

Committed to a more
sustainable future

COMPANY OVERVIEW





Senfina is a leading pharmaceutical technology company, aiming to become global **full service CDMO** for **vaccines and other pharmaceutical forms**

New Standard in CDMO Services

- ▶ Innovative capabilities, processes and design, specifically designed for vaccines and other pharmaceutical forms
- ▶ Modular production design that allows a new level of flexibility and quality
- ▶ Sophisticated design allows production licensing to external partners, making local production in emerging markets feasible

A Wealth of Experience

- ▶ Decades of experience with legacy companies and international senior leadership
- ▶ Highly capable team with strong track record in pharmaceutical companies and CDMO services
- ▶ Established relationships with key public health stakeholders and customers

Compelling Financial Proposition

- ▶ Significant order book already secured prior to capital investment
- ▶ Early focus on capital investment in infrastructure offers low-risk investment opportunity
- ▶ Attractive stock price offering with rapid roadmap to IPO

A new company with decades of history and key relationships
with stakeholders

~



MARKET OVERVIEW& UNMET NEEDS



High demand for local vaccine production in Africa and across Emerging Markets

Emerging markets are especially impacted by capacity restraints

Foreign production capacity often diverted away from emerging markets to higher priced countries


COVID-19 response has cannibalized capacity used for supplies for African and emerging markets



Shortages of vaccines have been reported as an increasing concern in the European Union (EU) and globally


Anticipated increased number of countries will report stock outs due to COVID-19

Number of Countries reporting Vaccine Stock Out




Strong underlying market growth drivers in key strategic CDMO segments

Long-term vaccine demand expected to grow with higher vaccination rates in emerging markets and on-going COVID-19 response growth



Hundreds of new vaccines candidates are in development for both emerging and established vaccination disease targets




Trend for further outsourcing of manufacturing by big pharma as well as emerging Biotech growth companies

Trend to outsource to CDMO, market projected to increase 8-10% growth for Vaccine CDMO services

- COVID 19 vaccine production dominating demand
- Non-Covid vaccine production deprioritized
- Long and complex manufacturing including multiple quality controls
- Unpredictability of global demand
- Growth in personalised medicine & gene-targeted therapeutics
- Increasing need for flexible, small batch production lines


Projected Market Growth
CDMO services 2 \$ billion



Insulin market expected to significant increase due to increases in Diabetes associated with COVID-19

- Demand for insulin expected to increase significant in association with COVID-19
- Basic access to insulin and diabetic treatments in Africa still limited
- Significant need expected for further insulin capacity, especially for emerging markets

With large and growing numbers of people worldwide infected with SARS-CoV-2,¹⁰ any COVID-19-related increases in diabetes incidence could lead to unprecedented cases of diabetes worldwide¹¹



Dr. R. Glavan,
Former Minister of Health, Moldova



High demand for local insulin production in Middle East and across Emerging Markets

Current levels of insulin access are disproportionately inadequate in the African, Asian. The regions projected to increase insulin use most if access were improved.

Diabetes is rising worldwide but it is reaching an epidemic level in the Middle East countries. The Middle East and North Africa region has the highest percentage (24.5%) of diabetes-related deaths in people of working age in the world.





SENFINA OVERALL SERVICES



Our Services –A compelling value proposition for established and growing pharmaceutical companies

Senfina provides a brand independent CDMO service that caters vaccine, other liquids and solid forms to pharmaceutical companies as well as innovative developers that need a production partner for their products



Specialty CDMO services

GMP Production:

API for bulk and small batch requirements

Fill & Finish in various formulations : vial,

PFS

OSD production

Packaging:

Customized packaging solutions based on each client's needs

Primary & secondary packaging, serialize and processing

Logistics:

Full warehousing and distribution capabilities

Production Localization & Licensing

Facility Design Licensing:

Licensing of Senfinamodular production design for local partners

Advisory in set up and production planning

API Supplier:

API supply for local production partners

Infrastructure Financing

Capital pool to support local partner production

Business Development

Senfina is planning to acquire biotech company to develop drugs.

The development team is already in contact with different companies

Due to increasing diabetic worldwide as a result of COVID-19 infection (ref: WHO) , Senfina has acquired OSD production site in Romania to expand product portfolio and deploy solid insulin production in the EU.

Our production design, created specifically for vaccines pharmaceutical liquids and other medical forms

Our modular approach in production brings a new standard in flexible production lines that allow a rapid setup of the production line and the ability to produce wide range of batches and broader spectrum of products within a production cycle.



| Key Features | Benefits to the Customer | Design & Development Partner  SGE PHARMA CONSULTING |
|---|--|---|
| Formulation, Fill & Finish Modular set up of production line Broad range of filling and packaging solutions (i.e. vials, pre-filled syringes, capsules, tablets, sachets) Design utilizing reliable technology | <ul style="list-style-type: none">Multiple vaccines formulations & filling at the same time in PFS or vials•Highest BPE (bioprocessing equipment) standard and no contamination risk•Wide range of batch sizes (20l-500l)•High percentage of IPC at each production line•Ability to produce a broader range of vaccines in more efficient approaches•Production of more SKU's based on market needs•Efficiently run small batch sizes for clinical development and personalized medicine•High-speed, automatic fill and finish lines•Flexible production line design that can accommodate most customer needs•Achieving highest standards of safety for employees, products, and environment. | |



SENFINA PRODUCTION



Acquisition of an existing OSD production site in Romania marked one of Senfina's 1st partnered venture in the EU market



Facility Facts and Figures

| | |
|---|---|
| Size | 28,000 sqm |
| Design Principles | Flexible production line Sustainable engineering |
| Product Capabilities | Full-service contract development and production of solid dosage forms (tablets, capsules and sachets). Full-service contract production of vaccines (Inactivated, Subunit, Toxoid, Conjugated, Recombinant vector, mRNA, DNA) |
| Production Capacity after capability expansion | 600,000,000 Tablets/year 60,000,000 Vials/year 30,000,000 PFS/year |
| Expansion completion | OSD 2025 Fill and Finish 2026 |





PRODUCTS

~

EXISTING PRODUCT PORTFOLIO

| | Product Name | Strength | Form | Status | IP status |
|-----------|--|---|-----------------|--|--|
| 1 | Diazepam | 2, 5, 10 mg | Tablets | MA in the EU (multiple countries) | IP owned by customer, SANTA acts as CDMO |
| 2 | Folic Acid | 0.4, 1, 5, 4.62 mg | Tablets | MA in the EU (multiple countries) | IP owned by customer, SANTA acts as CDMO |
| 3 | Methadone | 2.5, 5, 10, 20, 40 mg | Tablets | MA in the EU (multiple countries) | IP owned by customer, SANTA acts as CDMO |
| 4 | Naproxen | 250, 500 mg | Tablets | MA in the EU (multiple countries) | IP owned by customer, SANTA acts as CDMO |
| 5 | Oxazepam | 5, 10, 15 mg | Tablets | Development completed | IP owned by customer, SANTA acts as CDMO |
| 6 | Paracetamol/Codeine | 500/30, 500/8, 500/15, 1000/30, 1000/60 mg | Tablets | MA in the EU (RO) | IP owned by customer, SANTA acts as CDMO |
| 7 | Acetylsalicylic Acid | 500 mg | Tablets | MA in the EU (RO, FR, BE) | IP owned by Santapharm |
| 8 | Acetylsalicylic Acid + CaCO3 | 100, 500 mg | Tablets | MA in the EU (RO) | IP owned by Santapharm |
| 9 | ASA/Paracetamol/Caffeine | 250/250/50 mg | Tablets | CTD ready | IP owned by Santapharm |
| 10 | Bromhexine | 2, 8 mg | Tablets | MA in the EU (RO) | IP owned by Santapharm |
| 11 | Carbamazole | 5, 20 mg | Tablets | CTD ready, BEQ required | IP owned by Santapharm |
| 12 | Clonazepam | 0.5, 2 mg | Tablets | MA in the UK | IP owned by Santapharm |
| 13 | Dexamethasone | 0.5, 1, 2, 4 mg | Tablets | MA in UK | IP owned by Santapharm |
| 14 | Dextrometorphan | 10 mg, 20 mg | Tablets | MA in the EU (RO) | IP owned by Santapharm |
| 15 | Fludrocortisone | 0.1 mg | Tablets | CTD ready, BEQ in Canada completed, EU/ROW BEQ Required | IP owned by Santapharm |
| 16 | Methamizole Sodium | 500 mg | Tablets | MA in the EU (RO) | IP owned by Santapharm |
| 17 | Paracetamol | 500 mg | Tablets | MA in the EU (RO) | IP owned by Santapharm |
| 18 | Paracetamol | 500 mg | Coated Tablets | CTD ready | IP owned by Santapharm |
| 19 | Paracetamol/Chlorefeniramine | 500/3 mg | Tablets | MA in the EU (RO) | IP owned by Santapharm |
| 20 | Paracetamol/Pseudoephedrine/Chlorefeniramine | 500/50/3 mg | Tablets | MA in the EU (RO) | IP owned by Santapharm |
| 21 | Prednisolone | 5 mg | Tablets Soluble | MA in UK | IP owned by Santapharm |
| 22 | Temazepam | 10, 20 mg | Tablets | CTD ready in 2022 | IP owned by Santapharm |
| 23 | Tizanidine | 2, 4 mg | Tablets | CTD ready in 2022 | IP owned by Santapharm |

- 11 products are actively being manufactured (based on Annex 8 :In Progress & New applications
- Current portfolio: Anxiolytics, Cold&Flu, Painkiller, Glucocorticoid, Opioid, Folic acid
- Pipeline: Hypertension, Antidepressant, Hyperthyroidism, Painkiller, Corticosteroid

PRODUCTS IN PIPELINE / UNDER REGISTRATION

In Progress : 12 – 18 months

| Product Name | Category | Company |
|-------------------------|-----------------------------|---|
| Diazepam | Anxiolytic / benzodiazepine | Stada - PL |
| Methadone | Opioid | AFT- Australia- NZ |
| Paracetamol/ Codeine | Painkiller | Alissa Healthcare Research Limited - UK Lyrus Life Sciences Limited - UK |
| Fludrocortisone acetate | Corticosteroid | Accel Pharma - Canada |

Existing Santa Pharm product pipeline

The strategy :

- New clients for existing products
- New products for new clients
- First hypertension and antidepressant products are in the pipeline.

New applications: 6-9 months (+12/18 months)

| Product Name | Category | Company |
|-------------------------|-------------------------------|----------------------------------|
| Diazepam | Anxiolytic / benzodiazepine | Orbit - UK |
| Oxazepam | Anxiolytic / benzodiazepine | GPI - xxxx |
| Clonazepam | Anxiolytic / benzodiazepine | xxxx |
| Temazepam | Anxiolytic / benzodiazepine | xxxx |
| Folic Acid | Gynocology | GPI/TEVA - IT Orbit - UK |
| Carbimazole | Hyperthyroidism | xxxx |
| Naproxen | Painkiller | PBI - Vietnam Orbit - UK |
| Paracetamol | Painkiller | UK Santa (cpr filamte) - RO |
| Paracetamol & Ibuprofen | Pain | AFT |
| Sertralina HCL | Antidepressant (SSRI) | Rivopharm |
| Fosinopril | Hypertension (ACE inhibitor) | Rivopharm |

EXISTING SERVICES

Contract packaging services

SANTA SA offers the following packaging services in full compliance with all GMP regulations:

Primary and secondary packaging of bulk tablets and capsules

together with releasing of the batches on the EU markets.

Secondary packaging of bulk blisters

and releasing of the batches on the EU markets.

Rerepackaging and relabeling of products for the EU Parallel market

and providing the necessary batch file record required by the regulatory authorities of EU member countries.

Contract quality services

The quality services provided to third parties, performed in our quality control laboratory, and by the regulatory affairs team consist of the below-listed activities:

Quality control of API's and excipients

performed to third party partners from the EU.

Analytical method transfers and batch retest of products

with valid marketing authorization in EU countries but produced by contract manufacturers outside the EU.

Batch Release on EU markets

products with valid marketing authorization in EU countries but produced by contract manufacturers outside the EU.

Stability testing according to ICH guidelines

(accelerated, intermediate, long term, bulk stability, holding time, photostability, in use, open pot, thermal cycling and zone IVb)

Complete validation and documentation

of all methods and procedures relevant for drug registration according to all EU-, ICH- and any country specific requirements identified by the clients.

Selected New Product, Strength & Form (OSD)

| Therapeutic Area | API | Reference product | Strength | Form |
|------------------|---------------|-------------------------|----------|----------------|
| Diabetes | Sitagliptin | Januvia | 100 mg | tablet |
| | | | 50 mg | tablet |
| | | | 25 mg | tablet |
| Diabetes | Alogliptin | Nesina (Vipidia) | 6.25 mg | coated -tablet |
| | | | 12.50 mg | coated -tablet |
| Diabetes | | Empagliflozin Jardiance | 25 mg | coated -tablet |
| | | | 10 mg | tablet |
| | | | 25 mg | tablet |
| Allergy | Desloratadine | Claritin | 5 mg | coated -tablet |
| Allergy | Fexofenadine | Allegra | 120 mg | coated -tablet |
| | | | 180 mg | coated -tablet |
| Hypertension | Fosinopril | Monopril | 10 mg | tablet |
| | | | 20 mg | tablet |
| | | | 40 mg | tablet |
| Hypertension | Felodipine | Plendil | 2.5 mg | XR-tablet |
| | | | 5 mg | XR-tablet |
| | | | 10 mg | XR-tablet |
| Antidepressant | Sertraline | Zoloft | 25 mg | tablet |
| | | | 50 mg | tablet |
| | | | 100 mg | tablet |
| Antidepressant | Duloxetine | Cymbalta | 20 mg | EC capsule |
| | | | 30 mg | EC capsule |
| | | | 40 mg | EC capsule |
| | | | 60 mg | EC capsule |

SELECTED NEW PRODUCT (F&F LIQUIDS)


| Product # | Therapeutic Indication | Example: Commercial Name & Company | Type of vaccine | FORMS |
|-----------|--|--|-----------------|-------|
| 1 | DTaP-IPV | Kinrix - GSK (Global names : Infanrix IPV , PolioInfanrix, Vacina Adsorvida, Infanrixtetra) Quadracel - Sanofi | Inactivated | Vials |
| 2 | DTaP-IPV | GSK + SANOFI Havrix 1440 Adult & 720 Junior - GSK (HAVpur; Havrix; Havrix Junior; Hepatitis A Vaccine; Nothav; Virohep A) | Inactivated | PFS |
| 3 | HAV | Vaqta - MSD Epaxal - Boryung Pharmaceutical Co Ltd Hepatitis A vaccine - Changchun Changsheng Biological Technology Co Ltd - China Sinopharm International Corp Havrix 1440 Adult & 720 Junior - GSK (HAVpur; Havrix; Havrix Junior; Hepatitis A Vaccine; Nothav; Virohep A) | Inactivated | Vials |
| 4 | HAV | Vaqta - MSD Epaxal - Boryung Pharmaceutical Co Ltd Hepatitis A vaccine - Changchun Changsheng Biological Technology Co Ltd - China Sinopharm International Corp | Inactivated | PFS |
| 5 | Meningococcal Conjugate (Groups A, C, Y and W-135) | Menactra - Sanofi Mencevo - GSK Mencevax ACWY - Pfizer | Inactivated | Vials |
| 6 | Meningococcal Conjugate (Groups A, C, Y and W-135) | Menactra - Sanofi Mencevo - GSK Mencevax ACWY - Pfizer | Inactivated | PFS |
| 7 | Pneumococcal | Prevenar 13 - Pfizer | Inactivated | Vials |
| 8 | Pneumococcal | Prevenar 13 - Pfizer | Inactivated | PFS |
| 9 | Pneumococcal | PNEUMOVAX 23 - MSD (Pneumovax, Pneumo 23) Vaxneuvance- MSD Synflorix- GSK | Inactivated | Vials |
| 10 | Pneumococcal | PNEUMOVAX 23 - MSD (Pneumovax, Pneumo 23) Vaxneuvance- MSD Synflorix- GSK | Inactivated | PFS |
| 11 | Quadrivalent influenza vaccine (recombinant, prepared in cell culture) | Flucelvax Quad- Seqirus Ltd Flucelvax Tetra- CSL Ltd | Inactivated | Vials |
| 12 | Quadrivalent influenza vaccine (recombinant, prepared in cell culture) | Supermtek - Sanofi Flucelvax Quad- Seqirus Ltd Flucelvax Tetra- CSL Ltd | Inactivated | PFS |
| 13 | OTHERS | | Inactivated | Vials |
| 14 | FLU+COVID | Fluzone HD and Covid-19 vaccine | BSL1 | Vials |
| 15 | FLU+COVID | Fluzone HD and Covid-19 vaccine | BSL1 | PFS |
| 16 | Flu vaccine | Flublok quadrovalelnd recombinant DNA | BSL1 | Vials |
| 17 | Flu vaccine | Flublok quadrovalelnd recombinant DNA | BSL1 | PFS |

SENFINA PROJECTS



~


Senfina's production design allows the final stages of production to be completed in EU and emerging markets



Production site in UAE will be another significant partnered venture




CDMO Campus in Basel-land Switzerland to expand capacity and fuel growth of Senfina




The slide features a map of Switzerland with a green arrow pointing to the location of the new facility in Liestal, Basel. An inset provides a detailed view of the facility's layout, showing various buildings and production areas. To the right, a table titled "Facility Facts and Figures" contains the following information:

| Facility Facts and Figures | |
|-----------------------------------|--|
| Size | 35,000 sqm |
| Design Principles | Vaccine production center including social areas / Warehousing / Energy buildings With Sustainable engineering |
| Product Capabilities | 2 API production facilities All Major Vaccine Technologies <ul style="list-style-type: none">• Inactivated vaccines• Subunit• Toxoid• Conjugated• Recombinant vector• mRNA• DNA |
| Production Capacity per annum | API: 25,500-40,000 kg |
| 1 st line in operation | 2030 |
| Ground -breaking | 2026 |

Our Near-and Medium-Term Strategy is Focused on Growth through Capacity Expansion





Trading & Distribution channel with Interport ltd UK

(Member of Senfina Group)



OUR TRADING COMPANY

In the realm of veterinary products, it is widely acknowledged that prices tend to be high in Europe and the USA, largely due to the presence of certain manufacturers enjoying a monopoly. In this regard we plan a proactive approach in manufacturing veterinary medicines and vaccines for the Indonesian market within our state-of-the-art facility located in Romania. This strategic decision promises to revolutionize the price point structures, making them significantly more favorable for our valued customers in Indonesia. Furthermore, the establishment of a seamless and uninterrupted supply chain will ensure smooth imports and supplies, meeting the needs of the Indonesian veterinary healthcare sector efficiently and effectively.

We are a UK based pharmaceutical wholesalers established in 1982 specializing in Parallel Imported Products, Generics, OTC products throughout the UK, Europe, Africa and most of the world. We are fully licensed to operate, and we are regulated by the MHRA.





Financials & Investments



Phase Ia: Manufacturing Site Acquisition Romania & Extension plan by 2024 (OSD)

2023




Acquisition cost is € 15 MM

Extension cost is € 62 MM

PHASE 1-Manufacturing site Acquisition Total MM €

| 2023 | Fees & Contingencies | € 15 |
|------|-----------------------|-------------|
| 2024 | Other Furniture | € 2 |
| | Computer & IT | € 2 |
| | Electric & Automation | € 3 |
| | Energies & Equipment | € 10 |
| | Licences & Permits | € 10 |
| | Fees & Contingencies | € 5 |
| | Buildings & HVAC | € 10 |
| | Machinery | € 20 |
| | TOTAL | € 77 |

Phase Ib: New Fill & Finish Facility in Brasov, Romania




| PHASE 1 - MM € | |
|-----------------------|-------|
| Other Furniture | € 10 |
| Computer & IT | € 4 |
| Electric & Automation | € 20 |
| Energies & Equipment | € 28 |
| Fees & Contingencies | € 28 |
| Buildings & HVAC | € 35 |
| Machinery | € 45 |
| TOTAL | € 170 |

Total Phase I investment is € 170 MM


Phase IIa: New Site CAMPUSin UAE for API production (until BSL 2)

Total Phase IIa investment is € 510MM






| PHASE 2 API Production | - MM € |
|------------------------|--------------|
| Other Furniture | € 25 |
| Computer & IT | € 15 |
| Electric & Automation | € 40 |
| Energies & Equipment | € 120 |
| Fees & Contingencies | € 50 |
| Buildings & HVAC | € 150 |
| Machinery | € 100 |
| Labs | € 10 |
| TOTAL | € 510 |

Phase IIb: Extension in UAE for further Fill and Finish Total Phase IIb investment is € 300MM



| PHASE 2 - Insulin Production | - MM € |
|------------------------------|--------------|
| Other Furniture | € 15 |
| Computer & IT | € 10 |
| Electric & | |
| Automation | € 25 |
| Energies & | |
| Equipment | € 30 |
| Licences & Permit | € 10 |
| Fees & | |
| Contingencies | € 40 |
| Buildings & HVAC | € 80 |
| Machinery | € 80 |
| Labs | € 10 |
| TOTAL | € 300 |

Phase III: Capacity Expansion in Basel –Liestal Total Phase III investment is € 727 MM



Other Furniture

| Computer & IT PHASE 2a API Production - MM € | |
|--|--------------|
| Other Furniture | € 12 |
| Computer & IT | € 5 |
| Electric & Automation | € 18 |
| Energies & Equipment | € 38 |
| Licences & Permit | € 10 |
| Fees & Contingencies | € 40 |
| Buildings & HVAC | € 116 |
| Machinery | € 82 |
| TOTAL | € 321 |

| PHASE 2b Production 2 - MM € | |
|------------------------------|--------------|
| Other Furniture | € 12 |
| Computer & IT | € 5 |
| Electric & Automation | € 14 |
| Energies & Equipment | € 32 |
| Licences & Permit | € 6 |
| Fees & Contingencies | € 35 |
| Buildings & HVAC | € 107 |
| Machinery | € 75 |
| TOTAL | € 286 |


| General Site Investments - MM € | |
|---------------------------------|--------------|
| Administration Building | € 40 |
| Parkings Building | € 8 |
| Warehouse Building | € 42 |
| Energy Building | € 17 |
| Restaurant Building | € 7 |
| Pforte / Entrance | € 1 |
| Others | € 5 |
| TOTAL | € 120 |

Total Investment Plan including Acquisitions: 1.8 Bn €




| | |
|-----------|-------------------------------|
| Phase I | Brasov, Romania |
| Phase II | Dubai, UAE |
| Phase III | API Production in Switzerland |


Senfina Investment Plan – EUR MM




Senfina Revenue Plan – EUR MM



SefinaRevenue vs Investment -EUR MM



2021-2030 Total Investment vs Revenue –EUR MM





Alternative Markets / Veterinary products Proposal for Indonesia



List of product categories which can be produced in Romania now

- ANTIPARASITICS: Medications used to treat parasitic infections, such as anthelmintics (e.g., ivermectin) and antiprotozoals (e.g., metronidazole), may be used in both humans and animals.
 - CORTICOSTEROIDS: Corticosteroids, such as prednisone and dexamethasone, have applications in both human and veterinary medicine for their anti-inflammatory and immunosuppressive properties.
 - NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS): NSAIDs like aspirin, ibuprofen, and naproxen are commonly used in both human and veterinary medicine to alleviate pain and reduce inflammation.
- ANTIFUNGALS: Certain antifungal medications, such as fluconazole and ketoconazole, may be prescribed for both humans and animals to treat fungal infections.
-

List of product categories which can be produced in Romania after revamp

Following an investment in creating a manufacturing space for producing antibiotics for veterinary use we will be able to cover various pharmaceutical forms to suit different animal species, sizes, and administration needs.

Some common pharmaceutical forms of antibiotics used in veterinary medication include:

1.Oral Tablets and Capsules: Antibiotics are often formulated into oral tablets or capsules, making it convenient to administer to animals that can take medication orally. These forms may be designed to be swallowed whole or mixed with food.

2.Oral Liquids: Antibiotics can be formulated as liquid suspensions or solutions for oral administration. These forms are particularly useful for animals that may have difficulty swallowing tablets or capsules.

3.Injectable Solutions: Antibiotics can be prepared as sterile injectable solutions for administration by intramuscular (IM) or subcutaneous (SC) injection. Injectable antibiotics allow for rapid and effective delivery of the medication.

4.Topical Creams and Ointments: Certain antibiotics are formulated as topical creams or ointments for the treatment of localized skin infections or wounds in animals.

5.Otic (Ear) Preparations: Antibiotics in otic form are used to treat ear infections in animals. These formulations are designed for safe and effective application in the ear canal.

6.Ophthalmic (Eye) Preparations: Antibiotics in ophthalmic form are used to treat eye infections in animals. They are formulated for safe application to the eye.

7.Intravenous (IV) Solutions: Some critically ill animals may require IV administration of antibiotics. IV solutions are prepared to ensure accurate dosing and rapid delivery of the medication.

8.Intramammary Preparations: Antibiotics formulated as intramammary preparations are used to treat mastitis in lactating animals. These formulations are applied directly into the mammary gland.

Many of the above technologies could be also extended for corticosteroids too.



ANTIBIOTICS: Certain antibiotics are used in both human and veterinary medicine to treat bacterial infections.

Examples: include penicillin, tetracycline, and fluoroquinolones

VETERINARY VACCINES: NovibacRabies, NovibacDHP, Leptospira (Leptoferm), Vanguard Plus S

DIABETICS: Sitaslipin, Aloglipin,

Empagliblozin

ALLERGY: Desloratadin, Fexofenadine

HYPERTENSION: Fosinopril, Felodipine

Senfina Licenses

A certificate of GMP (Good Manufacturing Practice) Compliance of a Manufacturer is a document that certifies that a manufacturing facility complies with GMP standards. GMP is a set of quality assurance guidelines and regulations that ensure pharmaceutical, biotechnology, and medical device manufacturers maintain consistent and high quality production practices. Obtaining a Certificate of GMP Compliance is crucial for manufacturers as it demonstrates their commitment to producing safe and effective products.

CERTIFICATE OF GDP COMPLIANCE OF A WHOLESALE DISTRIBUTOR Nº UK WDA(H) 6176 INSP GDP
0017-421408/6176

A Certificate of GDP (Good Distribution Practice) Compliance is a document issued to a wholesale distributor in the pharmaceutical industry, indicating that the distributor has met the requirements and standards of GDP.

WHOLESALE DISTRIBUTION AUTHORIZATION (WDA) ISSUED BY MHRA Nº6176

Wholesale Distribution Authorization (WDA) is a license granted to Senfina that allows it to engage in wholesale distribution activities of pharmaceutical products or medicinal goods. It is a regulatory requirement and is issued by the MHRA that is responsible for overseeing the distribution of pharmaceuticals.

The purpose of a Wholesale Distribution Authorization is to ensure that Senfina complies with certain standards and regulations to safeguard the quality, safety, and efficacy of pharmaceutical products throughout the supply chain.

MANUFACTURING AND IMPORTATION LICENSE | HEALTH AND SAFETY LICENSE | ENVIRONMENT
PROTECTION LICENSE | CONTROLLED SUBSTANCES LICENSE | LABOR PROTECTION CERTIFICATE
WASTEWATER TREATMENT CERTIFICATE

OUR COLLABORATION PROPOSAL

1 New production facility in Indonesia

With our internally world wide recognized engineering competences, we aim to plan, develop, and ensure the construction of a new facility in your country through a joint venture.

This facility can be utilized for the production of veterinary products as well as essential human medicines.

3 Preparation / Revamping existing production

Senfina is ready to organize the revamp of an existing building in our Romanian facilities to produce essential veterinary products needed in Indonesia


2 Producing and delivering our Products

Senfina is interested in entering a joint venture to produce and deliver our existing products to Indonesia, if there is a demand for these products in the market.

4 Organization & Delivery other needs

Senfina, through our parallel imports and distribution channels, aims to provide other products (both human and veterinary medicines) to Indonesia.

Roadmap To Intial Public Offering



DISCLAIMER

This presentation is intended exclusively for the person or entity to which it is provided and contains information that is confidential and proprietary to Senfina Holding Ltd. It is strictly not for further distribution and must not be copied, reproduced, distributed, or passed to others at any time without the prior written consent of Senfina Holding Ltd.

The material provided in this presentation has been prepared for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase any security, product, or service. It does not constitute investment, legal, accounting, tax, or other professional advice, and recipients should consult with their own professional advisors before taking action based on this information.

The information herein is provided "as is" and Senfina Holding Ltd makes no representation or warranty of any kind regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information in the presentation. The company, its affiliates, and their respective officers, directors, employees, and agents expressly disclaim any and all liability that may be based on such information, errors therein, or omissions therefrom.

The information presented includes forward-looking statements that involve risks and uncertainties, and actual results may differ materially from those discussed. Senfina Holding Ltd assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the company, whether as a result of new information, future events, or otherwise.

Prospective investors should not place undue reliance on the forward-looking statements in this presentation. An investment in Senfina Holding Ltd involves substantial risks and uncertainties. Past performance is not indicative of future results, and no assurance can be given that the company's future performance will be comparable to past performance or that the company's business objectives will be achieved.

Prospective investors are strongly recommended to conduct their own due diligence, including a thorough review of Senfina Holding Ltd business, financial condition, and prospects, before making an investment decision.

Senfina Holding Ltd reserves the right to amend or replace the information contained herein at any time but has no obligation to update any information provided to the recipient.